book_title | section_heading | file_path | line_start | line_end | snippet -----------+-----------------+-----------+------------+----------+--------- Sleisenger and Fordtran's Gastrointestinal and Liver Disease | REFERENCES | /textbooks/9780323609623/9780323609623_block24.md | 4052 | 4062 | ...Lenatinib versus >>>sorafenib<<< in first-line >>>treatment<<< of patients with unresectable >>>hepatocellular<<< >>>carcinoma<<<: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–73. 136. Bruix J, Qin S... GOLDMAN-CECIL MEDICINE INTERNATIONAL EDITION, 2 VOLUME SET | GENERAL REFERENCES | /textbooks/9780323930345/9780323930345_block24.md | 3257 | 3269 | ...>>>Regorafenib<<< for patients with >>>hepatocellular<<< >>>carcinoma<<< who progressed on >>>sorafenib<<< >>>treatment<<< (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66. A5. Abou-Alfa GK... GOLDMAN-CECIL MEDICINE INTERNATIONAL EDITION, 2 VOLUME SET | GENERAL REFERENCES | /textbooks/9780323930345/9780323930345_block24.md | 3120 | 3132 | ...>>>Regorafenib<<< for patients with >>>hepatocellular<<< >>>carcinoma<<< who progressed on >>>sorafenib<<< >>>treatment<<< (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66. A5. Abou-Alfa GK... Goodman & Gilman’s The Pharmacological Basis of Therapeutics | Regorafenib | /textbooks/9781264258079/9781264258079_block19.md | 2765 | 2767 | ...>>>Regorafenib<<< is approved for the >>>treatment<<< of patients with metastatic colorectal cancer after previous chemotherapy, anti-VEGF therapy, or anti-EGFR therapy; for patients with >>>hepatocellular<<< >>>carcinoma<<< who have been... Harrison’s Principles of Internal Medicine 22E (2025, McGraw Hill Medical) | TREATMENT | /textbooks/9781265977061/9781265977061_block10.md | 376 | 379 | ...progressing on >>>sorafenib<<<: >>>regorafenib<<<, cabozantinib, and ramucirumab (only in patients with AFP >400 ng/mL). Therefore, these treatments have been adopted by guidelines and incorporated into the >>>treatment<<< algorithm. Patients... Harrison’s Principles of Internal Medicine 22E (2025, McGraw Hill Medical) | Locoregional therapies | /textbooks/9781265977061/9781265977061_block10.md | 414 | 418 | ...>>>Treatment<<< strategy for advanced >>>hepatocellular<<< >>>carcinoma<<< with systemic therapies. Drugs in bold have positive results from phase 3 trials with regulatory approval (atezolizumab plus bevacizumab, durvalumab plus tremelimumab, >>>sorafenib<<<, lenvatinib... Yamada's Textbook of Gastroenterology, 3 Volume Set, 7th e | First-line therapy | /textbooks/9781119600169/9781119600169_block20.md | 3141 | 3149 | ...This led to two randomized trials that compared TARE to >>>sorafenib<<< in advanced HCC. The first of these was the SARAH (>>>SorAfenib<<< Versus Radioembolization in Advanced >>>Hepatocellular<<< >>>Carcinoma<<<) trial [256... Sleisenger and Fordtran's Gastrointestinal and Liver Disease | Surgical Resection | /textbooks/9780323609623/9780323609623_block24.md | 3056 | 3063 | ...The >>>treatment<<< strategy will transition from one stage to another when >>>treatment<<< fails or is contraindicated. (Adapted from Forner A, Reig M, Bruix J. >>>Hepatocellular<<< >>>carcinoma<<<. Lancet 2018;391:1301...